• Estrogens are female hormone used to compete for androgen receptor sites, which decreases the influence of androgens (testosterone and androsterone) on prostate cancer. (chemocare.com)
  • This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen receptor-pathway inhibitor therapy. (dana-farber.org)
  • Vagia E, Economopoulou P, Oikonomopoulos N, Athanasiadis I, Dimitriadis G, Psyrri A. Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment. (mitera.gr)
  • All current forms of androgen-deprivation therapy (ADT) function by either lower levels of circulating androgens or blocking the binding of androgen to the androgen receptor. (urotoday.com)
  • Mutations in the androgen receptor have been documented that cause antiandrogen compounds to act like receptor agonists. (basicmedicalkey.com)
  • 2 , 3 In addition, genetic variations in the androgen receptor exist. (basicmedicalkey.com)
  • Activation of the androgen receptor is inversely correlated with CAG repeat length. (basicmedicalkey.com)
  • Halotestin or trenbolone called a luteinizing hormone-releasing hormone (LHRH) the androgen receptor. (viamarathon.org)
  • 2]The premise of androgen ablationrelies on growth of most prostate carcinomacells being androgen-dependent.The androgen receptor expressedby these cells binds dihydrotestosterone,which is then transported intothe nucleus, leading to a cascade ofevents that induces cellular growth. (cancernetwork.com)
  • The exact mechanism is not known and there may be many things happening since the androgen receptor is the key signalling pathway in prostate cancer,' he said. (bioengineer.org)
  • These two anti-cancer therapies work by inhibiting androgen receptor signalling. (bioengineer.org)
  • Gonadotropin or LHRH deficiency increase nitrogen retention in your prepare for the androgen receptor, the biological target of androgens like testosterone. (onevpn.com)
  • Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells ( PMID: 9428389 ). (jax.org)
  • The aim of the present study was to evaluate the expression of receptors for luteinizing hormone-releasing hormone (LHRH) in human specimens of triple-negative breast cancers (TNBC). (uni-luebeck.de)
  • Yasir S , Fernandez-Castro G, Bajwa N, Block N, Schally A, Cote R, Jorda M. Immunohistochemical expression of receptors for luteinizing hormone-releasing hormone (LHRHR) in muscle-invasive Urothelial carcinoma of urinary bladder: a potential predictive marker for targeted cytotoxic LHRH hybrid analog Surgical and Experimental Pathlogy. (mayoclinic.org)
  • Drugs commonly used for prostate cancer include luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists and androgen synthesis inhibitors. (sutterhealth.org)
  • Androgen deprivation therapy with a luteinizing hormone-releasing hormone (LHRH) agonist plus an antiandrogen should be used prior to radiation therapy for patients with locally advanced prostate cancer to improve outcomes over radiation therapy alone. (basicmedicalkey.com)
  • The predomination of an androgen-independent phenotype canoccur approximately 1 to 2 years afterthe initiation of androgen deprivation.Multiple strategies have been usedto induce serum levels of testosteronesimilar to those following castration.Traditional treatment options for androgenblockade include orchiectomy,luteinizing hormone-releasing hormone(LHRH) agonists and antagonists,nonsteroidal antiandrogens, andestrogens. (cancernetwork.com)
  • Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). (jax.org)
  • Triptorelin is an analog of luteinizing-hormone-releasing hormone (LHRH), which suppresses gonadotropin secretion, leading to decreased testosterone production in males ( PMID: 31500470 ). (jax.org)
  • In addition, we used in vitro and in vivo models of TNBC to investigate if these receptors are suitable targets for the treatment with the LHRH antagonist Cetrorelix. (uni-luebeck.de)
  • Referred to as complete androgen blockade, or CAB, this treatment choice combines an orchiectomy or LH-RH antagonist with anti-androgens, drugs that block the effects of adrenal gland hormones by influencing a receptor in the nucleus of the prostate cancer cell. (bcm.edu)
  • Must have remained on testosterone suppression for metastatic disease continuously (without treatment breaks) for 540-750 days (approximately 18 to 24 months) from time of first dose of LHRH agonist or antagonist by time of registration. (dana-farber.org)
  • LHRH agonists work by telling the pituitary gland located in the brain to stop producing leutinizing hormone, which (in men) stimulates the testicles to release testosterone and (in women) stimulates the ovaries to release estrogen. (chemocare.com)
  • Two endogenously occurring Galanin receptor agonists [Galanin (7-29) and Galanin 9-29) ]have been described from the porcine adrenals. (diabetesobesity.org.uk)
  • Traditionally, treatments for prostate cancer have involved lowering the levels of the male hormone (or androgen) testosterone using drugs called luteinising hormone-releasing hormone (LHRH) agonists, as it was thought that androgens stimulate the cancer cells to grow. (bioengineer.org)
  • The latter effect seems to be related to the down-regulation of receptors for GnRH. (utmb.edu)
  • The effects of inhibin on LH secretion may be secondary to the effects on Bio-GnRH receptors in bihormonal gonadotropes. (utmb.edu)
  • A monoclonal antibody (Mab) designated as GHR106 was generated against the extracellular domain (N1-29 synthetic peptide) of human gonadotropin releasing hormone (GnRH) receptor. (annexpublishers.co)
  • Both Mabs in murine (mGHR106) or humanized (hGHR106) forms were shown to have comparable specificity and affinity to intact GnRH receptor on cancer cells or to N1-29 synthetic peptides from humans and monkeys. (annexpublishers.co)
  • Gonadotropin releasing hormone (GnRH), both types I and II, is a decapeptide hormone that stimulates the release of gonadotropin, luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary through specific binding to the GnRH receptor located on the external membrane of selected cell types [ 1-3 ]. (annexpublishers.co)
  • Subsequent studies revealed that GnRH and its receptor also play extra-pituitary roles in numerous normal and malignant cells or tissues, the mechanisms of which are still being actively explored [ 4-6 ]. (annexpublishers.co)
  • They act by hyper-stimulation of GnRH receptors on the gonadotroph cells of the pituitary, resulting in an initial phase of elevated levels of testosterone and androgens, followed by down-regulation of the receptors. (biomedcentral.com)
  • These are GnRH antagonists, which immediately block the GnRH receptors to access by native GnRH peptides. (biomedcentral.com)
  • After secretion of GnRH-secreting neurons in the hypothalamic preoptic area, GnRH is transported by blood through the hypothalamic-pituitary-gonadial axis to the pituitary gland, which contains gonadotropic cells, with receptive GnRH receptors - a seven receptor G-protein coupled transmembrane called gonadotropin-releasing hormone receptor (GnRHR). (peptidesforresearch.com)
  • The significance of the expression of aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker, for predicting the recurrence of estrogen receptor (ER)-positive/human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is still poorly understood. (biomedcentral.com)
  • For patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer receiving adjuvant chemotherapy, endocrine therapy for 5 years plus additional chemotherapy for high-risk groups, such as patients with high tumor burden, advanced histological grade, and/or strong Ki-67 expression, is considered to improve survival. (biomedcentral.com)
  • Background Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). (unimi.it)
  • Several Galanin receptor antagonists have been synthesised which show high affinity for the Galanin receptor making an in vivo pharmacological use feasible. (diabetesobesity.org.uk)
  • Receptor antagonists with tissue specific receptor affinities are available which distinguish between pancreatic and CNS Galanin receptors. (diabetesobesity.org.uk)
  • At the same time the men continued on their LHRH agonist therapy to clamp down on testosterone produced naturally by the testicles. (bioengineer.org)
  • Premenopausal women and men also had an LHRH agonist in addition to an aromatase inhibitor - that could have been either letrozole or anastrozole - then randomized to ribociclib or placebo. (medscape.com)
  • Many members of this class of receptors occur in the cytoplasm and are transported to the CELL NUCLEUS upon ligand-binding where they signal via DNA-binding and transcription regulation. (edu.au)
  • About 70 percent of breast cancers contain estrogen receptors and can have their growth stimulated by the presence of estrogen. (sutterhealth.org)
  • Before prescribing hormone therapy, your doctor will likely have a tissue sample from your biopsy or surgery tested for estrogen receptors. (sutterhealth.org)
  • If no estrogen receptors are present, the cancer is termed ER-negative. (sutterhealth.org)
  • Blocking the ability of estrogen to stimulate cell growth - Selective estrogen receptor modulators (SERMs) bind to the estrogen receptors on the cells, preventing estrogen from binding. (sutterhealth.org)
  • Clomid, as does Nolvadex, works by occupying the binding sites of estrogen receptors of cells, without activating the receptors. (mrsarm.store)
  • Duration of adjuvant hormonal therapy and HR receptor status at progression are also helpful for further discussion. (practiceupdate.com)
  • Because the expression of the estrogen receptor (ER) in patients with primary breast cancer is one of the most powerful indicators of response to adjuvant hormonal therapy, the effects of endocrine-therapeutic agents strongly depend on whether tumor cell growth remains estrogen responsive ( 3 ). (iiarjournals.org)
  • Peptides derived from sequence of cell surface proteins, such as intercellular adhesion molecule-1 (ICAM-1), LHRH, Bombesin, and LFA-1, have shown potent binding affinity to the target cell surface receptors. (biosyn.com)
  • Moreover, peptides derived from ICAM-1 receptor can be internalized by the leukemic T-cells along with the conjugated moiety offering the promise to selectively treat cancers and autoimmune diseases. (biosyn.com)
  • Arg-Gly-Asp (RGD) peptides,2 poly-Arg peptides), 3,4 proteins (e.g., antibodies,5 transport proteins, and transferrin6), and small molecules (e.g., folate7) have been used to selectively direct drugs to cancer cells with upregulated receptors by forming drug-carrier conjugates (Fig. 1). (biosyn.com)
  • Most prostate cancer cells have receptors for testosterone and are potential targets for hormone therapy. (sutterhealth.org)
  • Androgen deprivation therapy, with either orchiectomy, an LHRH agonist alone or an LHRH agonist plus an antiandrogen (combined hormonal blockade), can be used to provide palliation for patients with advanced (stage D 2 ) prostate cancer. (basicmedicalkey.com)
  • Other brain chemicals and nerve signals also play roles in LHRH secretion and may be adversely affected by alcohol. (un23.ro)
  • These alterations were exclusively found in patients treated with adjuvant aromatase inhibitors or LHRH analogs plus tamoxifen, but not in patients treated with tamoxifen alone. (unimi.it)
  • Receptors for LHRH were expressed in all tumor samples and in the TNBC cell lines HCC1806 and HCC1937. (uni-luebeck.de)
  • The use of hormone therapy to treat cancer is based on the observation that receptors for specific hormones that are needed for cell growth are on the surface of some tumor cells. (chemocare.com)
  • Hormone therapy can work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell. (chemocare.com)
  • For example, tumor cells have certain upregulated receptors, enzymes, and other metabolic features that are not present in normal cells in the body. (biosyn.com)
  • Denosumab is a fully human monoclonal antibody that targets the receptor activator of the nuclear factor-kappa-B ligand (RANKL), which acts as the primary signal to promote bone removal. (medscape.com)
  • We found previously that nuclear receptors (NRs) compete for heterodimerization with their common partner, retinoid X receptor (RXR), in a ligand-dependent manner. (bvsalud.org)
  • Tumors of mice treated with Cetrorelix expressed less mRNA for EGFR and HER3 receptors than untreated tumors. (uni-luebeck.de)
  • Documentation of histological or cytological confirmation of estrogen receptor positive ( ER+ ) and HER2 negative adenocarcinoma of the breast must be available. (mycancergenome.org)
  • Could come as early this rS, Vraniak f-region of the receptor also can affect the activities of estradiol and 4-hydroxytamoxifen (Schwartz. (onevpn.com)
  • This reduces the extent to which estradiol can activate these receptors. (mrsarm.store)
  • The cytokine receptors lack intrinsic kinase activity and require interaction with members of the Jak family of intracellular signaling molecules. (jneurosci.org)
  • The receptors are responsive to one or more B7 ANTIGENS found on ANTIGEN-PRESENTING CELLS and, depending upon the specific ligand-receptor combination, modulate a variety of T-cell functions such as the rate of clonal expansion, CELL SURVIVAL and cytokine production. (edu.au)
  • Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. (harvard.edu)
  • The phosphorylated receptor provides multiple docking sites that recruit STAT proteins, of which there are six family members (STAT1-6) ( Pellegrini and Dusanter-Fourt, 1997 ). (jneurosci.org)
  • Here, we studied the effects of Dox on the chromatin binding of the architectural proteins high mobility group B1 (HMGB1) and the linker histone H1, and the transcription factor retinoic acid receptor (RARα) by fluorescence recovery after photobleaching (FRAP) and fluorescence correlation spectroscopy (FCS) in live cells. (bvsalud.org)
  • Included under this heading are signaling receptors, non-signaling receptors and accessory proteins required for receptor signaling. (edu.au)
  • However, adjuvant TAM is effective in some ER-negative breast cancer patients who express progesterone receptor (PgR), an ERG. (iiarjournals.org)
  • Pharmacologic therapy for osteoporosis includes most commonly the use of antiresorptive agents to decrease bone resorption, such as bisphosphonates, denosumab, and the selective estrogen-receptor modulator (SERM) raloxifene. (medscape.com)
  • Antiestrogens bind to estrogen receptor site on cancer cells thus blocking estrogen from going into the cancer cell. (chemocare.com)
  • These drugs bind themselves to the receptors on the cancer cells, preventing testosterone from binding to them and promoting cell growth. (sutterhealth.org)
  • If they are present, the cancer is termed estrogen-receptor positive, or ER-positive, and might respond to hormone therapy. (sutterhealth.org)
  • These differences could be in the expressed surface receptors (i.e., the absence or presence of certain receptors), the metabolism profiles (i.e., different enzyme expression or intracellular trafficking), the site/location of the cells (i.e., circulating in blood stream vs. organ), and the nature of the cells (i.e., normal vs. cancerous). (biosyn.com)
  • To investigate potential competition in their DNA binding, we monitored the mobility of retinoic acid receptor (RAR) and vitamin D receptor (VDR) in live cells by fluorescence correlation spectroscopy. (bvsalud.org)
  • Estrogens act by binding to and activating the estrogen receptor (ER), their biological target in the body. (wikipedia.org)
  • The spawning ratio was low in the group given a high dose of LHRH-a alone (50 µg/kg), while it was high in the groups given LHRH-a combined with high (20, 40 mg/kg) doses of MET, and in the group injected with CPE. (tubitak.gov.tr)
  • The relaxin receptor RXFP1 signals through a mechanism of autoinhibition. (harvard.edu)
  • This graph shows the total number of publications written about "Receptors, G-Protein-Coupled" by people in Harvard Catalyst Profiles by year, and whether "Receptors, G-Protein-Coupled" was a major or minor topic of these publication. (harvard.edu)
  • Below are the most recent publications written about "Receptors, G-Protein-Coupled" by people in Profiles. (harvard.edu)
  • Receptor activation causes Jak2 autophosphorylation, which phosphorylates its associated receptor. (jneurosci.org)
  • Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. (edu.au)
  • A family of receptors that modulate the activation of T-LYMPHOCYTES by the T-CELL ANTIGEN RECEPTOR. (edu.au)
  • Systematic analyses have revealed that physicochemical properties of the drug-peptide conjugates and their mechanism of receptor-mediated cellular internalization are important controlling factors for developing a successful targeting system. (biosyn.com)
  • It was concluded that spawning can be induced successfully in common carp broodstocks with 20 µg/kg LHRH-a+20 mg/kg MET, in a single injection, in a shorter latency period and without a negative effect on egg quality, compared to CPE treatment. (tubitak.gov.tr)
  • The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. (harvard.edu)
  • Cell surface receptors that are specific for INTERLEUKIN-1. (edu.au)
  • Immunobiology of natural killer cell receptors / E. Vivier and M. Colonna (eds. (edu.au)